See more : Astral Limited (ASTRAL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nanjing Hicin Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Carr’s Group plc (CARR.L) Income Statement Analysis – Financial Results
- Swiss Re AG (SSREF) Income Statement Analysis – Financial Results
- JIK Industries Limited (JIKIND.NS) Income Statement Analysis – Financial Results
- Country Group Holdings Public Company Limited (CGH.BK) Income Statement Analysis – Financial Results
- Eagon Industrial Co., Ltd. (008250.KS) Income Statement Analysis – Financial Results
Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ)
About Nanjing Hicin Pharmaceutical Co., Ltd.
Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517.83M | 526.47M | 578.32M | 706.30M | 924.54M | 711.91M | 455.03M | 280.83M | 220.99M | 197.66M | 169.50M | 147.95M |
| Cost of Revenue | 101.28M | 130.02M | 109.01M | 171.56M | 187.16M | 98.05M | 95.29M | 91.20M | 85.10M | 79.35M | 74.06M | 69.98M |
| Gross Profit | 416.56M | 396.45M | 469.30M | 534.73M | 737.38M | 613.86M | 359.75M | 189.63M | 135.89M | 118.31M | 95.44M | 77.97M |
| Gross Profit Ratio | 80.44% | 75.30% | 81.15% | 75.71% | 79.76% | 86.23% | 79.06% | 67.52% | 61.49% | 59.86% | 56.31% | 52.70% |
| Research & Development | 61.07M | 18.22M | 21.70M | 31.88M | 36.10M | 37.53M | 31.35M | 23.63M | 18.23M | 15.95M | 12.51M | 0.00 |
| General & Administrative | 23.82M | 16.50M | 18.86M | 12.53M | 14.26M | 14.10M | 9.11M | 7.26M | 5.68M | 5.87M | 5.42M | 24.12M |
| Selling & Marketing | 229.43M | 268.71M | 342.88M | 385.43M | 531.19M | 437.96M | 218.73M | 85.86M | 50.27M | 42.48M | 30.87M | 23.16M |
| SG&A | 315.16M | 285.21M | 361.74M | 397.96M | 545.45M | 452.05M | 227.84M | 93.12M | 55.95M | 48.34M | 36.29M | 47.28M |
| Other Expenses | 1.03M | -1.33M | 305.28M | -1.16M | -104.80K | -547.73K | -1.29M | 648.93K | 2.25M | 1.15M | 1.36M | -187.44K |
| Operating Expenses | 377.26M | 351.71M | 435.20M | 462.97M | 614.65M | 513.42M | 280.75M | 134.49M | 88.44M | 76.39M | 57.60M | 48.64M |
| Cost & Expenses | 478.54M | 481.73M | 544.21M | 634.53M | 801.81M | 611.47M | 376.04M | 225.69M | 173.54M | 155.73M | 131.66M | 118.62M |
| Interest Income | 960.84K | 1.02M | 779.82K | 507.23K | 713.87K | 560.78K | 776.90K | 81.39K | 47.94K | 109.94K | 132.67K | -0.14 |
| Interest Expense | 8.34M | 7.25M | 7.50M | 7.01M | 5.97M | 4.05M | 1.12M | 1.79M | 1.72M | 1.92M | 273.18K | 847.64K |
| Depreciation & Amortization | 53.56M | 48.14M | 37.07M | 31.63M | 27.75M | 16.76M | 14.10M | 12.69M | 10.93M | 10.19M | 3.91M | -2.25M |
| EBITDA | 99.58M | 84.17M | 375.01M | 100.03M | 144.84M | 116.85M | 85.75M | 66.96M | 60.09M | 51.89M | 42.98M | 27.88M |
| EBITDA Ratio | 19.23% | 17.57% | 65.19% | 14.50% | 16.32% | 16.63% | 21.01% | 24.41% | 27.46% | 26.95% | 25.47% | 18.84% |
| Operating Income | 43.44M | 30.10M | 331.30M | 62.51M | 114.27M | 96.52M | 77.58M | 52.08M | 45.47M | 40.05M | 37.40M | 30.13M |
| Operating Income Ratio | 8.39% | 5.72% | 57.29% | 8.85% | 12.36% | 13.56% | 17.05% | 18.54% | 20.58% | 20.26% | 22.06% | 20.36% |
| Total Other Income/Expenses | -5.75M | -1.33M | -852.77K | -1.16M | -104.80K | -547.74K | -1.30M | -2.20M | 1.97M | -267.59K | 1.36M | -379.89K |
| Income Before Tax | 37.69M | 28.78M | 330.45M | 61.35M | 114.16M | 95.97M | 76.29M | 52.46M | 47.44M | 39.78M | 38.76M | 29.75M |
| Income Before Tax Ratio | 7.28% | 5.47% | 57.14% | 8.69% | 12.35% | 13.48% | 16.77% | 18.68% | 21.47% | 20.13% | 22.87% | 20.11% |
| Income Tax Expense | 1.37M | -3.35M | 45.61M | 6.82M | 17.00M | 12.75M | 10.69M | 7.22M | 7.11M | 5.57M | 5.47M | 4.16M |
| Net Income | 36.32M | 32.45M | 285.88M | 55.23M | 97.26M | 83.22M | 65.60M | 45.24M | 40.33M | 34.21M | 33.29M | 25.59M |
| Net Income Ratio | 7.01% | 6.16% | 49.43% | 7.82% | 10.52% | 11.69% | 14.42% | 16.11% | 18.25% | 17.31% | 19.64% | 17.30% |
| EPS | 0.30 | 0.27 | 2.38 | 0.46 | 0.81 | 0.69 | 0.56 | 0.50 | 0.45 | 0.38 | 0.37 | 0.00 |
| EPS Diluted | 0.30 | 0.27 | 2.38 | 0.46 | 0.81 | 0.69 | 0.56 | 0.50 | 0.45 | 0.38 | 0.37 | 0.00 |
| Weighted Avg Shares Out | 120.01M | 120.00M | 120.00M | 120.00M | 120.00M | 120.00M | 117.50M | 90.00M | 90.29M | 90.04M | 90.78M | 0.00 |
| Weighted Avg Shares Out (Dil) | 120.01M | 120.00M | 120.00M | 120.00M | 120.00M | 120.00M | 117.50M | 90.00M | 90.29M | 90.04M | 90.78M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports